Galectin Therapeutic (GALT)
$3.00 0.00 (0.00%)
17:09 EST GALT Stock Quote Delayed 15 Minutes
Previous Close $3.00
Market Cap 113.22M
PE Ratio -6.52
Volume (Avg. Vol.)
Day's Range 3.00 - 3.00
52-Week Range 2.72 - 6.06
Dividend & Yield N/A (N/A)
GALT Stock Predictions, Articles, and Galectin Therapeutic News
- From InvestorPlace
- From the Web
Looking for blockbuster potential? These five biotech stocks may have found it in treating NASH -- an untapped market of up to $35 billion.
25 Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").
The following stocks were moving the Manufacturing sector today.
The Manufacturing sector saw plenty of trading activity today, including the following leaders and losers.
This week, the overall grades of 29 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
The ratings of 27 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Developing successful Ebola and liver disease treatments is an incredibly risky opportunity for biotech stocks to create value.
From Market News Video
Investors eyeing a purchase of Galectin Therapeutics Inc (GALT) shares, but cautious about paying the going market price of $2.81/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July 2020 put at the $2 strike, which has a bid at the time of this writing of 25 cents..
From Simply Wall St
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-galt/galectin-therapeutics/news/we-think-galectin-therapeutics-nasdaqgalt-can-easily-afford-to-drive-business-growth/">Read More...</a></div>
From Analyst Ratings
In a report released today, Mayank Mamtani from B.Riley FBR maintained a Buy rating on Galectin Therapeutics (GALT – Research Report), with a price target of $8.00. The company’s shares closed last Monday at $3.53. According to TipRanks.com, Mamtani is a 3-star analyst with an average return of 1.9% and a 42.9% success rate. Mamtani
Navellier RatingsPowered by Portfolio Grader